<?xml version="1.0" encoding="UTF-8"?>
<p>These are aqueous intravenous polyclonal human immunoglobulin G (IgG) from pools of source plasma of screened healthy adult donors with high levels of RSV-neutralizing antibodies. The results of a phase 1 and a 2 study on RI-001 and RI-002, respectively, demonstrated that the preparation met acceptable pharmacokinetic and safety criteria, and achieved a fold-change increase in titer of anti-RSV neutralizing antibodies in patients (
 <xref rid="ref154" ref-type="bibr">Wasserman et al., 2017</xref>).
</p>
